- Home
- DBX vs HALO Comparison
DBX vs HALO Comparison
Compare DBX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- HALO
- Stock Information
- Founded
- DBX 2007
- HALO 1998
- Country
- DBX United States
- HALO United States
- Employees
- DBX N/A
- HALO N/A
- Industry
- DBX Computer Software: Prepackaged Software
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBX Technology
- HALO Health Care
- Exchange
- DBX Nasdaq
- HALO Nasdaq
- Market Cap
- DBX 8.2B
- HALO 7.4B
- IPO Year
- DBX 2018
- HALO N/A
- Fundamental
- Price
- DBX $28.74
- HALO $53.75
- Analyst Decision
- DBX Buy
- HALO Buy
- Analyst Count
- DBX 4
- HALO 9
- Target Price
- DBX $31.00
- HALO $63.56
- AVG Volume (30 Days)
- DBX 3.6M
- HALO 3.3M
- Earning Date
- DBX 05-08-2025
- HALO 05-06-2025
- Dividend Yield
- DBX N/A
- HALO N/A
- EPS Growth
- DBX 1.18
- HALO 55.40
- EPS
- DBX 1.48
- HALO 3.76
- Revenue
- DBX $2,541,600,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- DBX N/A
- HALO $25.77
- Revenue Next Year
- DBX $0.04
- HALO $18.01
- P/E Ratio
- DBX $19.42
- HALO $14.29
- Revenue Growth
- DBX 0.79
- HALO 25.64
- 52 Week Low
- DBX $20.68
- HALO $42.01
- 52 Week High
- DBX $33.33
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- DBX 52.44
- HALO 42.85
- Support Level
- DBX $28.44
- HALO $52.43
- Resistance Level
- DBX $29.06
- HALO $54.26
- Average True Range (ATR)
- DBX 0.63
- HALO 3.37
- MACD
- DBX -0.14
- HALO -0.70
- Stochastic Oscillator
- DBX 20.57
- HALO 27.16
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.